16 completed, 8 recruiting, 4 unknown, 3 withdrawn. 32 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 16, Recruiting 8, Unknown 4, Withdrawn 3, Suspended 1 |
| Phase 2 | 16 | Recruiting 7, Completed 5, Unknown 2, Withdrawn 2 |
Follow Obstructive Sleep Apnea: new trials by email Literature Review of Obstructive Sleep Apnea trials Research Report on Obstructive Sleep Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition - Obstructive Sleep Apnea, Sleep-disordered Breathing | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 24 | 2026-09-01 | 2026-09-21 |
| DRonabinol Treatment of OSA Dronabinol - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 120 | 2025-08-25 | 2026-11-05 |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| Impact of Exogenous Ketones on Sleep Disruption in Vulnerable Populations Ketone-IQ (1,3 Butanediol) - Obstructive Sleep Apnea, Sleep | Phase 1 | Suspended | Johns Hopkins University | 30 | 2025-01-29 | 2026-06-23 |
| Exploring the Use of Phototherapy to Improve CPAP Compliance Phototherapy - Obstructive Sleep Apnea | Phase 1 | Recruiting | University of Alberta | 30 | 2024-01-05 | 2026-05-08 |
| Trazodone on OSA Endotypes Placebo oral tablet, Trazodone Hydrochloride - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 18 | 2024-01-01 | 2025-02-06 |
| Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs IHL42X, Acetazolamide 250 MG, Dronabinol 2.5 MG - Obstructive Sleep Apnea | Phase 1 | Completed | Incannex Healthcare Ltd | 125 | 2023-09-08 | 2025-01-17 |
| Rescue Pharmacotherapy for OSA Placebo, Acetazolamide, Trazodone - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 70 | 2023-07-01 | 2026-07-15 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities Mild Intermittent Hypoxia, Sham MIH - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2023-01-01 | 2025-12-04 |
| Atomoxetine and DAW2022 on OSA Severity Placebo oral capsule, Atomoxetine Oral Capsule [Strattera] - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 18 | 2022-06-01 | 2026-07-10 |
| Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy Atomoxetine, Oxybutynin - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Unknown | Brigham and Women's Hospital | 22 | 2022-05-05 | 2023-10-18 |
| Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) Dosing 1: Atomoxetine, AD313 - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Apnimed | 15 | 2021-10-19 | 2023-04-07 |
| Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease? Supplemental Oxygen, Continuous Positive Airway Pressure Machine, Room Air - OSA, Sleep Apnea | Phase 1 | Completed | University of California, San Diego | 182 | 2021-10-08 | 2026-05-11 |
| Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration Solriamfetol 150 mg Oral Tablet - Narcolepsy, Obstructive Sleep Apnea | Phase 1 | Completed | Axsome Therapeutics, Inc. | 6 | 2021-08-27 | 2023-04-14 |
| A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose BAY2586116, Placebo - Obstructive Sleep Apnea | Phase 1 | Completed | Bayer | 36 | 2021-05-11 | 2023-03-01 |
| Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) TAK-925, Placebo - Obstructive Sleep Apnea | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 25 | 2019-11-21 | 2020-04-20 |
| A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea ACT-541468, Placebo - Obstructive Sleep Apnea | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 28 | 2019-03-14 | 2019-12-19 |
| Pharmacological Activation of HMN for OSA Aim 2 Placebo oral capsule, LTM1201AZ, LTM1201AT - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 16 | 2019-03-01 | 2022-09-21 |
| Pharmacological Activation of HMN for OSA Placebo oral capsule, LTM1201L, LTM1201LN - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 6 | 2018-10-30 | 2020-02-24 |
Showing 20 of 32. Sign in to see all of them.
Sleep Apnea, Obstructive (32) · Sleep Apnea Syndromes (10) · Ketosis (2) · Alzheimer Disease (1) · Apnea (1) · Behavior (1) · Cardiovascular Diseases (1) · Disorders of Excessive Somnolence (1) · Fatigue (1) · Gastroesophageal Reflux (1) · Heart Failure (1) · Hypertension (1) · Hypoxia (1) · Motor Activity (1) · Myocardial Infarction (1)
Dyssomnias (32) · Nervous System Diseases (32) · Respiration Disorders (32) · Respiratory Tract Diseases (32) · Sleep Disorders, Intrinsic (32) · Apnea (31) · Sleep Wake Disorders (31) · Sleep Apnea Syndromes (22) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Acid-Base Imbalance (2) · Acidosis (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Heart Diseases (2)
Atomoxetine Hydrochloride (4) · Acetazolamide (3) · Dronabinol (2) · Trazodone (2) · 1,3-butylene glycol (1) · Celecoxib (1) · Dexmedetomidine (1) · Eszopiclone (1) · Indomethacin (1) · Magnetic Resonance Spectroscopy (1) · Mirtazapine (1) · Occlusal Splints (1) · Omeprazole (1) · Oxygen (1) · Phototherapy (1)
Brigham and Women's Hospital (8) · Johns Hopkins University (2) · VA Office of Research and Development (2) · Academic Centre for Dentistry in Amsterdam (1) · Apnimed (1) · Axsome Therapeutics, Inc. (1) · Bayer (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Eisai Inc. (1) · Idorsia Pharmaceuticals Ltd. (1) · Incannex Healthcare Ltd (1) · Mackay Memorial Hospital (1) · Mayo Clinic (1) · Millennium Pharmaceuticals, Inc. (1) · Montefiore Medical Center (1)
United States (22) · Canada (3) · Australia (1) · Belgium (1) · Germany (1) · Japan (1) · Netherlands (1) · Taiwan (1)
Jonathan Jun, MD (2) · Scott A Sands, PhD (2) · Bharati Prasad, MD (1) · Ching-Lung Liu, MD (1) · Christopher E Kline, MS (1) · Daniel Rodenstein, MD (1) · Emir Redzepagic, MBBS (1) · Frank Lobbezoo, professor (1) · Janet M Bennett, M.Ed,CCC-SLP (1) · Jason H Mateika, PhD MS BS (1) · John G. Park, M.D. (1) · Kristen H Archbold, PhD, RN (1) · Marc J Poulin, PhD (1)
PMID 21632834, PMID 22131599, PMID 22572632, PMID 22893765, PMID 24815497, PMID 33305817, PMID 35306405, PMID 36805833, PMID 40135690, PMID 40158847, PMID 40848323, PMID 41025403, PMID 41781273, PMID 42730864
2018 (1), I01CX002632 (1)